- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05855889
Observational Study of the Management of Infants With Congenital CMV (cCMVnet)
Study Overview
Status
Conditions
Detailed Description
Cytomegalovirus (CMV) is the most frequent cause of congenital infection worldwide, occurring in 0.2-2% of live births. It is also the most frequent cause of non-genetic hearing loss, and an important cause of neurodevelopmental delay. Clinical diagnosis of maternal infection during pregnancy is unreliable in most patients and laboratory diagnosis can be challenging, especially in non-primary infections. Screening of congenital CMV infection (cCMV) in newborns is not recommended in most countries and only targeted screening is performed in some cases (children who fail hearing screening or with abnormalities compatible with cCMV in physical exams).
The main focus of the study is to identify patient and treatment characteristics that are associated with outcome. This will allow improved patient care in the future.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Sana Ibrahim, BSc
- Phone Number: +44 (0)208 725 5382
- Email: sibrahim@sgul.ac.uk
Study Locations
-
-
-
London, United Kingdom, SW17 0RE
- Recruiting
- St George's University of London
-
Contact:
- Sana Ibrahim, BSc
- Phone Number: +44 (0)208 725 5382
- Email: sibrahim@sgul.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria: Patients of either sex that have been diagnosed with cCMV infection:
- Through confirmed detection of CMV in urine or saliva, by CMV-DNA PCR (or viral culture / Shell-vial) and/or CMV detection in blood or CSF by PCR within the first 21 days of life.
- Children with cCMV retrospectively diagnosis by positive CMV-DNA PCR in dried blood spots (DBS), collected within 21 days of life.
- Diagnosed by positive CMV-DNA PCR in dried umbilical cord blood or donated/stored umbilical cord blood sample
- Children whose parents give their informed consent to participate in the study
- Age less than 11 years old
Exclusion Criteria:
- Refusal to sign written informed consent of parents/ legal guardian.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical characteristics
Time Frame: 15 years
|
To analyze the clinical characteristic of children born with cCMV (measure is number of participants with hearing loss, retinitis, neurological abnormalities, skin rashes, or hepatosplenomegaly)
|
15 years
|
Adverse events
Time Frame: 15 years
|
To document adverse events of different treatment strategies
|
15 years
|
Measuring cases of cCMV in the UK
Time Frame: 15 years
|
To analyze the epidemiology of children born with cCMV
|
15 years
|
To evaluate risk factors in children with cCMV for long term sequelae
Time Frame: 15 years
|
To measure the number of cases with abnormal brain imaging (cranial USS or MRI), hearing loss, retinitis or anaemia, leucopenia, thrombocytopenia, renal function or liver abnormalities at diagnosis
|
15 years
|
To evaluate the prognostic value of microbiological variables
Time Frame: 15 years
|
To measure the urine CMV viral load in cases at diagnosis who develop hearing loss
|
15 years
|
To evaluate the prognostic value of image findings
Time Frame: 15 years
|
To measure the number of cases who have abnormal brain imaging (cranial USS or MRI) at diagnosis and develop hearing loss
|
15 years
|
To evaluate associated outcomes with different treatment strategies
Time Frame: 15 years
|
To measure the number of cases treated with valganciclovir and the number of treated cases who need a treatment break
|
15 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Simon Drysdale, MD, St George's, University of London
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021.0118
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Cmv
-
St George's, University of LondonSt George's University Hospitals NHS Foundation TrustActive, not recruitingCMV | Congenital Cmv | Maternal Infections Affecting Fetus or Newborn | Shedding VirusUnited Kingdom
-
Albert ParkGenentech, Inc.; National Institute on Deafness and Other Communication Disorders...Active, not recruitingCmv Congenital | CMV | Congenital Cmv | SNHL | Sensorineural Hearing LossUnited States
-
New York Medical CollegeRecruiting
-
University of NebraskaCompletedCongenital CMV InfectionUnited States
-
University of Alabama at BirminghamRecruitingCmv Congenital | CMV ViremiaBrazil
-
Stony Brook UniversityFrontier Science & Technology Research Foundation, Inc.RecruitingSensorineural Hearing Loss | Congenital CMV InfectionUnited States
-
Assistance Publique - Hôpitaux de ParisTerminatedCongenital Cytomegalovirus (CMV)France
-
Grupo Espanol de trasplantes hematopoyeticos y...Not yet recruiting
-
QIAGEN Gaithersburg, IncTerminated